GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
By Elana Gotkine HealthDay Reporter
MONDAY, March 3, 2025 -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors in adjusted analyses, according to a study published online Feb. 26 in The BMJ.
Samantha B. Shapiro, from the Jewish General Hospital in Montreal, and colleagues conducted an active comparator, new user cohort study to examine whether use of GLP-1 receptor agonists is associated with an increased risk for suicidal ideation, self-harm, and suicide compared with DPP-4 inhibitor or SGLT-2 inhibitor use. The first cohort included 36,082 GLP-1 receptor agonist users and 234,028 DPP-4 inhibitor users, and the second cohort included 32,336 GLP-1 receptor agonist users and 96,212 SGLT-2 inhibitor users.
In crude analyses, the researchers found an increased incidence of suicidality with GLP-1 receptor agonist versus DPP-4 inhibitor use (crude incidence rates, 3.9 versus 1.8 per 1,000 person-years; hazard ratio, 2.08; 95 percent confidence interval, 1.83 to 2.36). After accounting for confounding factors, this estimate decreased to a null value (hazard ratio, 1.02; 95 percent confidence interval, 0.85 to 1.23). GLP-1 receptor agonist use was also associated with an increased risk for suicidality compared with SGLT-2 inhibitor use (crude incidence rates, 4.3 versus 2.7 per 1,000 person-years; hazard ratio, 1.60; 95 percent confidence interval, 1.37 to 1.87), but the correlation did not persist after accounting for confounding factors (hazard ratio, 0.91; 95 percent confidence interval, 0.73 to 1.12). When suicidal ideation, self-harm, and suicide were analyzed separately in both cohorts, the findings were similar.
"These findings should provide some reassurance with respect to the psychiatric safety of these drugs," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...
Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study...
Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes
FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.